The mission of the OSUCCC Biomedical Informatics Shared Resource (BISR) is to advance cancer research throughout the OSUCCC by providing end-users with advanced biomedical informatics services and expertise. End-users include OSUCCC leadership, investigators, research staff, trainees, and other shared resources (SRs) and scientific programs (SPs). In the last CCSG award cycle, the BISR was a developing shared resource and in this cycle will serve as a full shared resource. The BISR accomplishes its mission through a number of mechanisms, including the following specific services: 1) customization, deployment, and management of caBIG technologies and platforms in support of clinical and bio-molecular data management and integration requirements;2) the execution of complex data analyses that require bioinformatics and computational-biology expertise;and 3) biomedical informatics consulting, project planning, and training. The BISR is organized into two complementary arms, focusing on Computational Biology Services (CBS) and Data Management Services (DMS). The CBS arm of the BISR provides end-users with services, including the planning and execution of SP- or SR-specific data management applications and analytical workflows, with an emphasis on the utilization of high throughput biological data, such as that generated by OSUCCC instrumentation SRs. The DMS arm of the BISR provides technical services and expertise in support of the adoption, customization, and use of caBIG technologies and platforms to facilitate SP- and SR-specific data management requirements, with an emphasis on the provision of data-analytic pipelines that enable end-users to identify, integrate, exchange, and analyze heterogeneous and distributed data sets/sources. In addition, the DMS arm facilitates OSUCCC end-user access to enterprise-wide clinical informatics tools and data sources, such as the Medical Center's Information Warehouse (a comprehensive enterprise-wide data warehouse), as well as the data management tools and resources being developed by the CTSA-funded OSU Center for Clinical and Translational Science (CCTS). The BISR serves as a catalyst throughout the OSUCCC to integrate and rapidly translate discoveries from the lab to cancer treatment and prevention.

Public Health Relevance

The OSUCCC Biomedical Informatics Shared Resource (BISR) provides a suite of services, technologies, and expertise that support the timely and efficient conduct of basic, clinical, and translational research projects. The BISR provides OSUCCC members with access to: 1) informatics consultation services in order to assist such end-users to identify and engage informatics methods and tools throughout their active or planned activities;2) data management, exchange, and analysis tools and platform;and 3) complex data analysis methods requiring bioinformatics and computational-biology expertise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601810
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$208,821
Indirect Cost
$71,890
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9
Eloy, Josimar O; Petrilli, Raquel; Topan, José Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82
Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86
Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9
Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94
Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527
DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198
Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct. Mol Endocrinol 30:783-95

Showing the most recent 10 out of 1929 publications